At the time of writing, PTC Therapeutics Inc [PTCT] stock is trading at $48.82, up 0.25%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PTCT shares have gain 7.58% over the last week, with a monthly amount glided 0.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on June 17, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $80. Previously, BofA Securities upgraded its rating to Buy on May 09, 2025, and kept the price target unchanged to $68. On May 07, 2025, upgrade upgraded it’s rating to Neutral but maintained its price target of $40 on the stock. BofA Securities upgraded its rating to a Neutral and increased its price target to $55 on March 11, 2025. Scotiabank initiated its recommendation with a Sector Perform and recommended $55 as its price target on March 07, 2025. Morgan Stanley upgraded its rating to Overweight for this stock on December 13, 2024, and upped its price target to $67. In a note dated December 03, 2024, RBC Capital Mkts upgraded an Outperform rating on this stock and boosted its target price from $39 to $63.
For the past year, the stock price of PTC Therapeutics Inc fluctuated between $30.41 and $58.38. Currently, Wall Street analysts expect the stock to reach $70 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $48.82 at the most recent close of the market. An investor can expect a potential return of 43.38% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
According to PTC Therapeutics Inc [NASDAQ:PTCT], the company’s sales were 1.76B for trailing twelve months, which represents an -4.19% plunge. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.41%, Pretax Profit Margin comes in at 0.38%, and Net Profit Margin reading is 0.36%. To continue investigating profitability, this company’s Return on Assets is posted at 0.24, Equity is -0.99 and Total Capital is 0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.88.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 48.12 points at the first support level, and at 47.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 49.37, and for the 2nd resistance point, it is at 49.92.
Ratios To Look Out For
It is important to note that PTC Therapeutics Inc [NASDAQ:PTCT] has a current ratio of 3.62. As well, the Quick Ratio is 3.57, while the Cash Ratio is 1.62. Considering the valuation of this stock, the price to sales ratio is 2.20 and price to earnings (TTM) ratio is 7.00.
Transactions by insiders
Recent insider trading involved Boulding Mark Elliott, Officer, that happened on Aug 15 ’25 when 2813.0 shares were purchased. CHIEF EXECUTIVE OFFICER, Klein Matthew B. completed a deal on Aug 05 ’25 to sell 10739.0 shares. Meanwhile, Officer Klein Matthew B. bought 10739.0 shares on Aug 05 ’25.
